FDA issued its first DSCSA Form 483 to a physician-owned practice in 2026

  • Home
  • Practice Speciality
    • MedSpa
    • EyeCare
    • Oncology
    • Rhuematology
    • Dispensary / Pharmacy
    • Primary Care
  • What We Do
  • How It Works
  • Video's Blog & Articles
  • FAQ
  • Contact US
  • Assessment - Free
  • More
    • Home
    • Practice Speciality
      • MedSpa
      • EyeCare
      • Oncology
      • Rhuematology
      • Dispensary / Pharmacy
      • Primary Care
    • What We Do
    • How It Works
    • Video's Blog & Articles
    • FAQ
    • Contact US
    • Assessment - Free
  • Home
  • Practice Speciality
    • MedSpa
    • EyeCare
    • Oncology
    • Rhuematology
    • Dispensary / Pharmacy
    • Primary Care
  • What We Do
  • How It Works
  • Video's Blog & Articles
  • FAQ
  • Contact US
  • Assessment - Free

Find your exposure before the FDA finds it.

A Readiness Review identifies documentation gaps, sourcing risks, and reconciliation failures specific to your practice type. Delivered by someone who operates inside the regulated structure not a theoretical compliance advisor.

Take the Free Practice Assessment

What Happened?

The Drug Supply Chain Security Act (DSCSA) requires every entity that takes possession of a prescription drug to maintain a traceable chain of custody. This includes any injectable, infusion, biologic, or dispensed Rx product Botox, chemotherapy agents, anti-VEGF injections, GLP-1s, biologics, IV therapy, hormone replacement, immunotherapy, and more.


Enforcement expanded to physician practices and clinics in 2024. The FDA stabilization period ended August 2025. Full inspection mode is now active.


  • Every drug vendor is FDA-registered and verified
  • Records exist for every drug shipment received
  • Purchases reconcile to patient administration logs
  • A written procedure for suspect product is in place


Most practices have none of these. Not from bad intent because nobody told them it applied.

Is your specialty at risk? Select your practice type.

EyeCare
MedSpa
Oncology
Rheumatology
Primary Care
Medically Integrated Pharmacy

Frequently Asked Questions

FAQ

About the Founder

James Strafuss

James Strafuss is the President of MUSTEC LLC and founder of MedPharma USA, a licensed healthcare distribution platform serving physician practices, specialty clinics, and regulated healthcare manufacturers.


With more than two decades in federally regulated business environments, James has built operational systems for organizations under oversight from the SEC, the DOJ, and executive-level federal institutions.

He holds active Designated Representative (DR) status in multiple states carrying personal accountability for wholesale drug distribution, recordkeeping integrity, and Board of Pharmacy compliance.


His DSCSA expertise spans trading partner requirements, serialization, ATP validation, suspect product procedures, and transaction data reconciliation across manufacturers, distributors, and dispensers.

Unlike theoretical compliance advisors, James operates inside the regulated structure itself implementing controls across licensure, vendor credentialing, lot tracking, and inspection-readiness within active distribution environments.


Through Claritas Axis Group, he translates complex statutory requirements into executable operational systems helping practices understand where risk lives before an inspector finds it.


His work reflects direct accountability under the law not commentary on it.

Request a Readiness Review

For practices that want to understand their current exposure
Schedule Initial Call
  • Video's Blog & Articles
  • FAQ
  • Assessment - Free

Claritas Axis Group

Copyright © 2026 claritasaxis.com - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept